Boceprevir plus Peginterferon/Ribavirin to retreat HCV genotype-1 in HIV-HCV coinfected patients. Final results of BOC HIV-HCV Spanish Study

Highlights • Prospective, randomized clinical trial. • Safety and efficacy of RGT with BOC + pegylated interferon alpha 2a/ribavirin. • Retreatment of HCV-HIV coinfected patients with genotype-1 who were non-responders or relapsers to P/R therapy. • Overall sustained virological reponse of 67% up to...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of infectious diseases
Main Authors Laguno, M, Von Wichmann, M.A, Van den Eynde, E, Navarro, J, Cifuentes, C, Murillas, J, Veloso, S, Martínez-Rebollar, M, Guardiola, J.M, Jou, A, Sirvent, J.L. Gómez, Cervantes, M, Pineda, J.A, López-Calvo, S, Carrero, A, Montes, M.L, Deig, E, Tapiz, A, Ruiz-Mesa, J.D, Cruceta, A, de Lazzari, E, Mallolas, J
Format Journal Article
LanguageEnglish
Published 2016
Subjects
Infectious Disease
Pulmonary/Respiratory
HCV-HIV experienced patients
re-treatment
P/R + BOC therapy
HCV genotype 1
Online AccessGet full text

Cover

More Information
Summary:Highlights • Prospective, randomized clinical trial. • Safety and efficacy of RGT with BOC + pegylated interferon alpha 2a/ribavirin. • Retreatment of HCV-HIV coinfected patients with genotype-1 who were non-responders or relapsers to P/R therapy. • Overall sustained virological reponse of 67% up to 80% in previously relapsed or breakthrough to P/R. • Cost-effective alternative treatment in non available DAA settings.
ISSN:1201-9712
DOI:10.1016/j.ijid.2016.10.028